Clearside Biomedical (CLSD) is Initiated by Wedbush to Outperform, Price Target at $28

Clearside Biomedical (CLSD) was Initiated by Wedbush to “Outperform” and the brokerage firm has set the Price Target at $28. Wedbush advised their investors in a research report released on Jun 27, 2016.

Clearside Biomedical

Leave a Reply

Clearside Biomedical - Is it time to Sell?

Top Brokerage Firms are advising their investors on Clearside Biomedical. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.